Acadian Asset Management LLC Sells 277,611 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Acadian Asset Management LLC decreased its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 82.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 57,762 shares of the company’s stock after selling 277,611 shares during the period. Acadian Asset Management LLC owned approximately 1.93% of Tonix Pharmaceuticals worth $39,000 at the end of the most recent reporting period.

Separately, Armistice Capital LLC grew its holdings in shares of Tonix Pharmaceuticals by 160.0% during the 4th quarter. Armistice Capital LLC now owns 3,770,000 shares of the company’s stock valued at $1,519,000 after purchasing an additional 2,320,000 shares during the last quarter. Institutional investors own 82.26% of the company’s stock.

Analyst Upgrades and Downgrades

TNXP has been the topic of several recent research reports. StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Wednesday. They set a “sell” rating on the stock. Alliance Global Partners raised their target price on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

Shares of NASDAQ:TNXP opened at $0.15 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $0.38 and a 200-day moving average price of $3.52. The company has a market cap of $440,435.00, a price-to-earnings ratio of 0.00 and a beta of 2.09. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $0.13 and a 12 month high of $27.52.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Friday, August 16th. The company reported ($19.28) EPS for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). The business had revenue of $2.21 million for the quarter, compared to the consensus estimate of $3.50 million. Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. As a group, equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -12.37 EPS for the current year.

Tonix Pharmaceuticals Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.